Medtrum's 300U Patch Pump Gets German Reimbursement Code: 50% Capacity Boost
Medtrum's 300U tubeless insulin pump has been listed in Germany's statutory medical aids directory, a key step for reimbursement. The device offers 50% greater insulin capacity than standard patch pumps, potentially reducing device changes for high-dose patients. Healthcare providers and payers will weigh its integrated AID algorithm and real-world evidence as it moves toward commercial launch.
Key Takeaways
- Medtrum's 300U tubeless insulin pump has been listed in Germany's statutory medical aids directory, a key step for reimbursement.
- The device offers 50% greater insulin capacity than standard patch pumps, potentially reducing device changes for high-dose patients.
- Healthcare providers and payers will weigh its integrated AID algorithm and real-world evidence as it moves toward commercial launch.
Mentioned
Key Intelligence
Key Facts
- 1Medtrum's 300U tubeless patch pump offers 300 units of insulin capacity, a 50% increase over commonly used 200-unit patch pumps.
- 2The pump has been listed in Germany's statutory health insurance medical aids directory under a dedicated Hilfsmittelnummer, enabling reimbursement through the public system.
- 3It is part of the TouchCare Nano System, which integrates the APGO AID algorithm, continuous glucose monitoring, and Auto Meal Handling for simplified meal announcements.
- 4The device was presented at DDG 2026 in Berlin, alongside the theme “Medtrum macht mehr möglich” (“Medtrum makes more possible”).
- 5CEO Scott Yang stated the company plans to strengthen direct commercial operations, partnerships, and clinical evidence generation across Europe.
- 6The 300U pump is already available in selected international markets and will expand Medtrum's tubeless insulin delivery portfolio in Europe.
Reservoir size increases from 200 to 300 units in a tubeless form factor
Germany is one of Europe's leading diabetes technology markets, with strong clinical adoption, an established reimbursement framework and continued innovation.
Announcing progress toward German launch at DDG 2026
Analysis
For healthcare delivery systems, the addition of a higher-capacity tubeless insulin pump to Germany’s statutory reimbursement roster expands the toolset for managing type 1 diabetes. The 300U reservoir means patients with greater insulin needs may require fewer pump changes, which can improve adherence and reduce the burden on clinics monitoring frequent site rotations. Health IT integrations like Medtrum’s remote data sharing could further align with value-based care models.
At the Diabetes Kongress (DDG) 2026 in Berlin, Medtrum showcased its 300-unit tubeless insulin patch pump, advancing toward a commercial launch in Germany. The company, which operates globally in diabetes technology, announced that the higher-capacity device has been listed in Germany's statutory health insurance medical aids directory under a dedicated Hilfsmittelnummer. This administrative step is critical: it unlocks access to the nation's public reimbursement system, covering approximately 90% of the population, and signals a realistic pathway to market entry. For a medical device company, German reimbursement is a rigorous milestone that often serves as a bellwether for broader European adoption.
The 300U pump offers a 300-unit insulin reservoir, which Medtrum claims is 50% larger than the commonly used 200-unit patch pumps that dominate the tubeless market.
The 300U pump offers a 300-unit insulin reservoir, which Medtrum claims is 50% larger than the commonly used 200-unit patch pumps that dominate the tubeless market. For people with type 1 diabetes who require high daily insulin doses—due to insulin resistance, body mass, or lifestyle factors—larger reservoir capacity can mean fewer pump changes per week, potentially improving adherence and reducing therapy disruptions. Maintaining a discreet, tubeless form factor while expanding capacity addresses a specific patient subpopulation often underserved by current options. The pump belongs to the TouchCare Nano System, Medtrum's integrated platform that combines a tubeless patch pump, continuous glucose monitoring (CGM), the proprietary APGO automated insulin delivery (AID) algorithm, mobile app control, and remote data sharing. The system also features Auto Meal Handling, which allows users to announce a meal type rather than calculate exact carbohydrate counts—a simplification designed to lower the cognitive burden of diabetes management.
Medtrum's strategic focus on Germany is well-founded. The country is Europe's largest medical device market with an established reimbursement framework for diabetes technology, high clinical adoption of insulin pumps and CGM, and a population that includes a significant number of people with diabetes using advanced therapies. By securing a dedicated Hilfsmittelnummer, the 300U pump can be prescribed and reimbursed under statutory health insurance, removing a major financial barrier for patients and prescribers alike. CEO Scott Yang noted the company's intent to strengthen direct commercial operations, build partnerships, and generate clinical evidence—three pillars that suggest Medtrum aims to move beyond a distributor model to a direct presence in Europe.
What to Watch
The competitive landscape, however, is formidable. Insulet's Omnipod line, particularly the Omnipod 5 with its integrated AID, holds a strong position in the tubeless pump segment, and Medtronic's MiniMed with extended-wear infusion sets competes in the broader insulin delivery space. Medtrum will need to differentiate not only through capacity but also through proven algorithm performance, user experience data, and real-world outcomes. Clinical evidence for the APGO algorithm and Auto Meal Handling will be scrutinized by clinicians and payers. While the 300U pump is already available in selected international markets, no large-scale clinical trials or comparative effectiveness studies are mentioned in the company's announcement. This lack of independent validation could slow uptake among cautious European endocrinologists.
From a market perspective, the global insulin patch pump market is projected to grow at a compound annual growth rate north of 15%, driven by the shift toward tubeless designs, the integration of AID algorithms, and increasing reimbursement in developed nations. Medtrum's entry into Germany with a 300U option positions it to capture a niche that Insulet's current Omnipod reservoirs (200U) do not directly address. However, Insulet is widely expected to develop higher-capacity versions, and competition will intensify. Medtrum's emphasis on "making more possible" through a broader portfolio could resonate with patient advocacy groups and diabetes clinics seeking personalized therapy options. The coming months will reveal whether the company can convert this regulatory and reimbursement progress into meaningful market share and clinical confidence.
Cite This Page
"Medtrum's 300U Patch Pump Gets German Reimbursement Code: 50% Capacity Boost." Healthcare Intelligence Brief, July 27, 2026. https://gethealthbrief.com/story/medtrum-300u-patch-pump-german-reimbursement
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |